Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of L-Nil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG2 | P78540 | 4/20 | 0.51 |
| ▸ | NOS2 | P35228 | 6/20 | 0.50 |
| ▸ | NOS1 | P29475 | 5/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ARG1 | P05089 | 3/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | OTC | P00480 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Nil SCHEMBL677147 | 1.00 | ARG2 (0.51) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL7974005 | 1.00 | ARG2 (0.51) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL7977021 | 1.00 | ARG2 (0.51) | ARG2NOS2NOS1BLMARG1 | |
| Hydrochloric Acid SCHEMBL8470176 | 0.98 | ARG2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL31540966 | 0.98 | ARG2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL934874 | 0.98 | ARG2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL322091 | 0.98 | ARG2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| SCHEMBL8065968 | 0.97 | NOS2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| L-Nio SCHEMBL676368 | 0.95 | OTC (0.53) | ARG2NOS2NOS1BLMARG1 | |
| L-Nio SCHEMBL1320520 | 0.95 | OTC (0.53) | ARG2NOS2NOS1BLMARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307335-A1 | IRG Blockade to Armor CAR T Cells Against Myeloid Dysfunction | ROSWELL PARK CANCER INSTITUTE CORPORATION | 2024-09-19 | — | — | US | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| US-20240398889-A1 | NUTRACEUTICAL COMPOSITION AND METHOD FOR THE PROTECTION OF HUMAN ARTERIAL ENDOTHELIAL CELLS FROM ENDOTHELIAL CELL DYSFUNCTION | K.L.R.M., LLC | 2024-12-05 | — | — | US | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-20240307335-A1 | IRG Blockade to Armor CAR T Cells Against Myeloid Dysfunction | ROSWELL PARK CANCER INSTITUTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| US-20240180995-A1 | NUTRACEUTICAL COMPOSITION AND METHOD FOR THE PROTECTION OF HUMAN ARTERIAL ENDOTHELIAL CELLS FROM ENDOTHELIAL CELL DYSFUNCTION | K.L.R.M., LLC | 2024-06-06 | — | — | US | disclosed |
| WO-2024112683-A1 | NUTRACEUTICAL COMPOSITIONS AND METHODS FOR THE PROTECTION OF HUMAN ARTERIAL ENDOTHELIAL CELLS FROM ENDOTHELIAL CELL DYSFUNCTION | K.L.R.M., LLC (US) | 2024-05-30 | — | — | WO | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11911349-B2 | Rapidly improving vascular conditions by administering vitamin K | NATTOPHARMA AS (NO) | 2024-02-27 | — | — | US | disclosed |
| US-11439675-B2 | Method for treating damage induced by sleep deprivation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220160651-A1 | RAPIDLY IMPROVING ENDOTHELIAL FUNCTION, REDUCING ARTERIAL STIFFNESS AND REVERSING CALCIFICATION OF BLOOD VESSELS BY ADMINISTERING VITAMIN K | NATTOPHARMA AS (NO) | 2022-05-26 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-20160151424-A1 | AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-INFLAMMATION METHODS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2016-06-02 | — | — | US | disclosed |
| CN-101316602-B | Amniotic membrane preparations and purified compositions and methods of use thereof | TISSUETECH INC | 2015-06-03 | — | — | CN | disclosed |
| EP-2664337-A1 | Amniotic membrane preparations and purified compositions and methods of use | TissueTech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120258127-A1 | VACCINE PEPTIDES | THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD & RURAL AFFAIRS (GB) | 2012-10-11 | — | — | US | disclosed |
| US-8182841-B2 | Amniotic membrane preparations and purified compositions and anti-inflammation methods | TISSUE TECH, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20070231401-A1 | Amniotic membrane preparations and purified compositions and anti-inflammation methods | BIO-TISSUE, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160651-A1 | RAPIDLY IMPROVING ENDOTHELIAL FUNCTION, REDUCING ARTERIAL STIFFNESS AND REVERSING CALCIFICATION OF BLOOD VESSELS BY ADMINISTERING VITAMIN K | PROC, VDR, MYLK | ARG2 457/4885NOS2 8/4885NOS1 10/4885 |
| US-11439675-B2 | Method for treating damage induced by sleep deprivation | SI, CRY2, PER2 | ARG2 77/4885NOS2 357/4885NOS1 638/4885 |
| US-20240398889-A1 | NUTRACEUTICAL COMPOSITION AND METHOD FOR THE PROTECTION OF HUMAN ARTERIAL ENDOTHELIAL CELLS FROM ENDOTHELIAL CELL DYSFUNCTION | LIPG, NOS3, NOS2 | ARG2 18/4885NOS2 3/4885NOS1 4/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ARG2 20/4885NOS2 356/4885NOS1 558/4885 |
| US-20240180995-A1 | NUTRACEUTICAL COMPOSITION AND METHOD FOR THE PROTECTION OF HUMAN ARTERIAL ENDOTHELIAL CELLS FROM ENDOTHELIAL CELL DYSFUNCTION | LIPG, NOS3, NOS2 | ARG2 14/4885NOS2 3/4885NOS1 4/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | ARG2 1398/4885NOS2 1541/4885NOS1 1983/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ARG2 20/4885NOS2 356/4885NOS1 558/4885 |
| US-11911349-B2 | Rapidly improving vascular conditions by administering vitamin K | PROC, VDR, VEGFA | ARG2 444/4885NOS2 8/4885NOS1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.